Related Experiment Video
Updated: Sep 6, 2025
05:10
Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
Published on: December 11, 2016
9.7K
Systematic indication extension for drugs using patient stratification insights generated by combinatorial analytics
Sayoni Das1, Krystyna Taylor1, Simon Beaulah1
1PrecisionLife, Unit 8b Bankside, Hanborough Business Park, Long Hanborough OX29 8LJ, UK.
Patterns (New York, N.Y.)
|June 27, 2022
Summary
Drug repositioning offers a faster, cheaper, and de-risked path to new therapies for unmet medical needs. Advanced patient stratification and AI analytics identify numerous opportunities for drug indication extension, boosting innovation.
Area of Science:
- Drug discovery and development
- Pharmacology
- Biotechnology
Background:
- Drug repositioning and indication extension offer efficient routes to new therapies.
- Addressing unmet medical needs requires innovative approaches.
- High-resolution patient stratification is crucial for targeted therapies.
Purpose of the Study:
- To explore the potential and challenges of drug repositioning strategies.
- To evaluate the role of patient stratification in drug development.
- To identify opportunities for drug indication extension using advanced analytics.
Main Methods:
- Systematic analysis of development candidates and on-market drugs.
- Application of high-resolution patient stratification methodologies.
- Utilizing artificial intelligence (AI) and combinatorial analytics.
Main Results:
- Identified 477 indication extension opportunities across 30 chronic disease areas.
- Each opportunity is supported by patient stratification biomarkers.
- Demonstrated the potential of AI and analytics to enhance drug discovery innovation.
Conclusions:
- Drug repositioning presents significant clinical and commercial benefits.
- Patient stratification methodologies enhance disease insights and scalability.
- AI and combinatorial analytics can accelerate innovation in drug discovery.
Related Concept Videos
01:12Analysis of Population Pharmacokinetic Data
378
Analysis of population pharmacokinetic data involves studying the behavior of drugs within diverse populations to understand their pharmacokinetic parameters. Traditional pharmacokinetic methods typically involve collecting samples from a few individuals and estimating these parameters. While these methods are commonly used, they have limitations in capturing the variability in drug response among individuals or heterogeneous populations. Population pharmacokinetics is employed to address these...
378
01:26Drug Discovery: Overview
8.7K
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
8.7K
01:28Structure-Activity Relationships and Drug Design
1.0K
Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
1.0K
00:59Model-Independent Approaches for Pharmacokinetic Data: Noncompartmental Analysis
122
Noncompartmental analyses offer an alternative method for describing drug pharmacokinetics without relying on a specific compartmental model. In this approach, the drug's pharmacokinetics are assumed to be linear, with the terminal phase log-linear. This assumption allows for simplified analysis and interpretation of the drug's behavior in the body.
One important characteristic of noncompartmental analyses is that drug exposure increases proportionally with increasing doses. This...
One important characteristic of noncompartmental analyses is that drug exposure increases proportionally with increasing doses. This...
122
01:18Cardiovascular Drugs: Classification based on Therapeutic Indications
3.1K
Cardiovascular diseases, encompassing a range of conditions, can significantly affect the heart's operations and the overall circulatory system. These conditions impair the heart's ability to pump blood, leading to a deficit in oxygen supply to crucial organs. Anomalies in the heart's electrical system, known as arrhythmias, can cause heartbeats to accelerate or slow down. Usually, heart rates increase during physical activity and decrease while resting or sleeping. However,...
3.1K
01:11Clinical Trials: Overview
3.4K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
3.4K